Copy to clipboard 
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Fourth Quarter 2025
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,117.7 | $3,811.8 | $305.9 | 8% |
| Knees | $2,092.5 | $1,925.2 | $167.3 | 8.7% |
| Hips | $1,492.1 | $1,399.6 | $92.5 | 6.6% |
| Extremities | $533.1 | $487.0 | $46.1 | 9.5% |
| Spine | $274.2 | $260.5 | $13.7 | 5.3% |
| Trauma | $1,784.9 | $1,615.8 | $169.1 | 10.5% |
| Sports Medicine | $648.3 | $597.4 | $50.9 | 8.5% |
| Orthobiologics | $227.6 | $222.0 | $5.6 | 2.5% |
| Enabling Technology | $228.0 | $191.5 | $36.5 | 19.1% |
| Other | $722.9 | $679.9 | $43.0 | 6.3% |
| Total | $8,003.6 | $7,378.8 | $624.8 | 8.5% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $17,189.1 | $16,232.6 | $956.5 | 5.9% |
| Knees | $8,479.9 | $8,052.1 | $427.8 | 5.3% |
| Hips | $6,329.6 | $6,017.3 | $312.3 | 5.2% |
| Extremities | $2,379.6 | $2,163.2 | $216.4 | 10% |
| Spine | $3,630.6 | $3,450.0 | $180.6 | 5.2% |
| Trauma | $7,583.1 | $6,925.1 | $658.0 | 9.5% |
| Sports Medicine | $3,810.3 | $3,612.2 | $198.1 | 5.5% |
| Orthobiologics | $1,538.8 | $1,472.6 | $66.2 | 4.5% |
| Enabling Technology | $944.6 | $875.8 | $68.7 | 7.8% |
| Other | $3,005.7 | $2,675.7 | $330.1 | 12.3% |
| Total | $37,702.2 | $35,244.1 | $2,458.1 | 7% |
Total Orthopedic Sales for Reporting Companies
| Company | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| CONMED | $157.3 | $139.0 | $18.3 | 13.2% |
| J&J MedTech | $2,439.0 | $2,315.8 | $123.2 | 5.3% |
| SI-BONE | $56.4 | $49.0 | $7.3 | 15% |
| Stryker * | $3,107.2 | $2,851.9 | $255.3 | 9% |
| Zimmer Biomet | $2,243.8 | $2,023.2 | $220.6 | 10.9% |
| Company | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| CONMED | $574.5 | $543.9 | $30.6 | 5.6% |
| J&J MedTech | $9,257.8 | $9,158.0 | $99.7 | 1.1% |
| SI-BONE | $200.9 | $167.2 | $33.7 | 20.2% |
| Stryker * | $11,287.8 | $10,251.3 | $1,036.5 | 10.1% |
| Zimmer Biomet | $8,231.7 | $7,678.4 | $553.2 | 7.2% |
* Excluding 2024 and 2025 spine revenue
Orthopedic Market Developments for Fourth Quarter 2025
CONMED Turns In Strong 4Q Ortho Performance
The company spent recent quarters underperforming relative to the overall sports medicine market, but turned its fortunes around in the fourth quarter with more than 13% orthopedic growth.
J&J MedTech Closes Out 2025 with Better Ortho Performance
The company called out increased momentum for orthopedics with growth of 5.3% (3.5% after currency impact), driven by new product launches and better commercial execution. SKU rationalization and VBP impact in China offset some of the gains.
Stryker’s High-Growth Offense Surges to End 2025
The company set another record quarter for Mako installs, and now has a worldwide install base over 3,000 systems. Utilization numbers are impressive, as well. Two-thirds of Stryker’s U.S. knee implants are performed using Mako, while one-third of its U.S. hips use the robot.
Zimmer Biomet Embarks on US Channel Transformation
Given the improved, more comprehensive nature of Zimmer Biomet’s portfolio now, the company feels that it is the right time to overhaul its U.S. commercial channel. However, the process is sure to create some short-term disruption.
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Fourth Quarter 2025
Where applicable, company names...
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Fourth Quarter 2025
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,117.7 | $3,811.8 | $305.9 | 8% |
| Knees | $2,092.5 | $1,925.2 | $167.3 | 8.7% |
| Hips | $1,492.1 | $1,399.6 | $92.5 | 6.6% |
| Extremities | $533.1 | $487.0 | $46.1 | 9.5% |
| Spine | $274.2 | $260.5 | $13.7 | 5.3% |
| Trauma | $1,784.9 | $1,615.8 | $169.1 | 10.5% |
| Sports Medicine | $648.3 | $597.4 | $50.9 | 8.5% |
| Orthobiologics | $227.6 | $222.0 | $5.6 | 2.5% |
| Enabling Technology | $228.0 | $191.5 | $36.5 | 19.1% |
| Other | $722.9 | $679.9 | $43.0 | 6.3% |
| Total | $8,003.6 | $7,378.8 | $624.8 | 8.5% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $17,189.1 | $16,232.6 | $956.5 | 5.9% |
| Knees | $8,479.9 | $8,052.1 | $427.8 | 5.3% |
| Hips | $6,329.6 | $6,017.3 | $312.3 | 5.2% |
| Extremities | $2,379.6 | $2,163.2 | $216.4 | 10% |
| Spine | $3,630.6 | $3,450.0 | $180.6 | 5.2% |
| Trauma | $7,583.1 | $6,925.1 | $658.0 | 9.5% |
| Sports Medicine | $3,810.3 | $3,612.2 | $198.1 | 5.5% |
| Orthobiologics | $1,538.8 | $1,472.6 | $66.2 | 4.5% |
| Enabling Technology | $944.6 | $875.8 | $68.7 | 7.8% |
| Other | $3,005.7 | $2,675.7 | $330.1 | 12.3% |
| Total | $37,702.2 | $35,244.1 | $2,458.1 | 7% |
Total Orthopedic Sales for Reporting Companies
| Company | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| CONMED | $157.3 | $139.0 | $18.3 | 13.2% |
| J&J MedTech | $2,439.0 | $2,315.8 | $123.2 | 5.3% |
| SI-BONE | $56.4 | $49.0 | $7.3 | 15% |
| Stryker * | $3,107.2 | $2,851.9 | $255.3 | 9% |
| Zimmer Biomet | $2,243.8 | $2,023.2 | $220.6 | 10.9% |
| Company | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| CONMED | $574.5 | $543.9 | $30.6 | 5.6% |
| J&J MedTech | $9,257.8 | $9,158.0 | $99.7 | 1.1% |
| SI-BONE | $200.9 | $167.2 | $33.7 | 20.2% |
| Stryker * | $11,287.8 | $10,251.3 | $1,036.5 | 10.1% |
| Zimmer Biomet | $8,231.7 | $7,678.4 | $553.2 | 7.2% |
* Excluding 2024 and 2025 spine revenue
Orthopedic Market Developments for Fourth Quarter 2025
CONMED Turns In Strong 4Q Ortho Performance
The company spent recent quarters underperforming relative to the overall sports medicine market, but turned its fortunes around in the fourth quarter with more than 13% orthopedic growth.
J&J MedTech Closes Out 2025 with Better Ortho Performance
The company called out increased momentum for orthopedics with growth of 5.3% (3.5% after currency impact), driven by new product launches and better commercial execution. SKU rationalization and VBP impact in China offset some of the gains.
Stryker’s High-Growth Offense Surges to End 2025
The company set another record quarter for Mako installs, and now has a worldwide install base over 3,000 systems. Utilization numbers are impressive, as well. Two-thirds of Stryker’s U.S. knee implants are performed using Mako, while one-third of its U.S. hips use the robot.
Zimmer Biomet Embarks on US Channel Transformation
Given the improved, more comprehensive nature of Zimmer Biomet’s portfolio now, the company feels that it is the right time to overhaul its U.S. commercial channel. However, the process is sure to create some short-term disruption.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
